

COVID-19 vaccines – ACIP makes recommendations for 2024-2025 vaccine administration

- On June 27, 2024, the Centers for Disease Control and Prevention's (CDC) <u>Advisory Committee</u> on <u>Immunization Practice</u> (ACIP) unanimously voted for 2024 – 2025 COVID-19 vaccines as authorized or approved by the FDA in persons ≥ 6 months of age.
- <u>COVID-19</u> continues to occur in the U.S. population:
 - COVID-19-associated hospitalizations and deaths occur all year around, but peak in December – February
 - COVID-19-associated hospitalizations and deaths are highest in adults aged 75 and older
 - More pediatric hospitalizations and deaths occur each year associated with COVID-19 than other select vaccine preventable diseases.
- Previously, the <u>FDA advised</u> that the preferred JN.1-lineage for the COVID-19 vaccines (2024 2025 formula) is the KP.2 strain, if feasible.

What's Next?

- The FDA will approve or authorize COVID-19 vaccines for the 2024 2025 season.
- The CDC's director will endorse the ACIP's recommendations.
- The 2024 2025 vaccines are expected to be available by mid-August to September 2024.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.